AI-assisted care for Multiple Sclerosis
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study
This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | icometrix Industry-sponsored |
| Locations | 3 sites (Prague, Praha 2 and 2 other locations) |
| Trial ID | NCT06280755 on ClinicalTrials.gov |
What this trial studies
The RECLAIM study aims to create a centralized dataset to support the development of AI models that enhance diagnosis and prognosis for patients with Multiple Sclerosis and related conditions. By analyzing real-world data, the study seeks to optimize treatment strategies and monitor disease progression effectively. It focuses on differentiating between various forms of disease worsening and aims to develop MRI-based tools and biomarker models to improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed diagnosis of Multiple Sclerosis, NMOSD, MOGAD, Clinically Isolated Syndrome, or Radiologically Isolated Syndrome.
Not a fit: Patients under 18 years of age or those deemed unsuitable by the investigator will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with Multiple Sclerosis.
How similar studies have performed: Other studies utilizing AI and data-driven approaches in Multiple Sclerosis have shown promise, indicating potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS or RIS. * Patient (or patient's legal representative) has previously signed and dated an informed consent form (ICF) for the secondary use of their data, or assent form. Alternatively, the secondary use of the patient's data is allowed following Institutional Review Board (IRB)/Ethical Committee (EC) approval in accordance with national and local subject privacy regulations. Exclusion criteria: * Patients under 18 years of age will be excluded. * Other unspecified reasons that, in the opinion of the Investigator or Joint Steering Committee, make the patient unsuitable for participation in the study.
Where this trial is running
Prague, Praha 2 and 2 other locations
- General University Hospital Prague — Prague, Praha 2, Czechia (Recruiting)
- Katholisches Klinikum Bochum - St. Joseph-Hospital — Bochum, Bochum, Germany (Recruiting)
- ERC Charité - Universitätsmedizin Berlin — Berlin, State of Berlin, Germany (Recruiting)
Study contacts
- Principal investigator: Friedemann Paul, PhD, MD — Max Delbrück Center - Charite University, Berlin, Germany
- Study coordinator: Diana M Sima, PhD
- Email: diana.sima@icometrix.com
- Phone: +32 16 369 000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.